As of 2024-12-12, the EV/EBITDA ratio of Prometheus Biosciences Inc (RXDX) is -58.45. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Prometheus's latest enterprise value is 9,445.47 mil USD. Prometheus's TTM EBITDA according to its financial statements is -161.61 mil USD. Dividing these 2 quantities gives us the above Prometheus EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.1x - 16.5x | 15.0x |
| Forward P/E multiples | 15.0x - 17.7x | 15.8x |
| Fair Price | (48.47) - (53.26) | (49.51) |
| Upside | -124.2% - -126.6% | -124.8% |
| Date | EV/EBITDA |